Endocrine Dysfunction in Pediatric Wilson's Disease

A Cross-sectional Study of Endocrine Changes in Children With Wilson's Disease at Assiut University Children's Hospital

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07208565

Enrollment

Registered

2025-10-06

Start date

2026-06-30

Completion date

2027-12-30

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wilson's Disease

Keywords

Wilson's

Brief summary

This cross-sectional study investigates endocrine changes in children diagnosed with Wilson's disease, aiming to characterize hormonal dysfunctions affecting pituitary, thyroid, adrenal, and gonadal axes.

Detailed description

Wilson's disease (WD) is an inherited copper metabolism disorder leading to copper accumulation in various organs including endocrine glands. While hepatic and neurological effects are well-documented, endocrine manifestations remain insufficiently studied in children. This study will systematically assess hormonal axes-including pituitary, growth hormone, thyroid, adrenal, and gonadal functions-through clinical evaluation, pubertal staging, and biochemical tests. The study aims to measure the prevalence and spectrum of endocrine abnormalities in pediatric WD patients and correlate them with disease severity and therapy. Findings will highlight underrecognized complications that impact growth, puberty, and fertility, contributing to more comprehensive management of WD in children.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

3 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Children aged 3-18 years Confirmed diagnosis of Wilson's disease (based on clinical features, biochemical markers such as serum ceruloplasmin and 24-hour urinary copper) Both newly diagnosed and treated patients (chelation/zinc therapy) Informed consent from parents or guardians

Exclusion criteria

* Congenital or acquired endocrine disorders unrelated to WD (e.g., congenital hypothyroidism, pituitary tumors) Concurrent use of medications affecting hormonal function unless prescribed for WD (steroids, thyroid replacements, contraceptives) Chronic systemic illnesses that confound endocrine assessment (e.g., malignancy, chronic renal failure)

Design outcomes

Primary

Measure	Time frame	Description
prevalence of endocrine dysfunction in pediatric Wilson's disease	baseline	Identification and classification of hormonal abnormalities affecting pituitary, adrenal, thyroid, and gonadal axes at study enrollment

Outcome results